AtriCure (NASDAQ:ATRC) Stock Falls 6.2% – Time to Sell?

AtriCure, Inc. (NASDAQ:ATRC) shares fell 6.2% on Thursday. The stock traded as low as $52.60 and last traded at $52.7120. 1,021,907 shares traded hands during mid-day trading, an increase of 17% from the average session volume of 875,922 shares. The stock had previously closed at $56.20.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on ATRC shares. Zacks Research lowered AtriCure from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 24th. Piper Sandler boosted their price target on AtriCure from $50.00 to $60.00 and gave the company an “overweight” rating in a report on Thursday, August 27th. Citigroup restated a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st. BTIG Research lifted their price objective on AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, August 24th. Finally, Weiss Ratings upgraded AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 19th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $53.30.

AtriCure Price Performance

The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. The company has a market cap of $2.70 billion, a P/E ratio of 252.05 and a beta of 1.26. The firm’s fifty day moving average is $48.63 and its two-hundred day moving average is $36.08.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. The business had revenue of $153.60 million for the quarter, compared to analysts’ expectations of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same period last year, the firm earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, analysts anticipate that AtriCure, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling at AtriCure

In related news, insider Salvatore Privitera sold 4,519 shares of the company’s stock in a transaction on Wednesday, September 23rd. The shares were sold at an average price of $60.00, for a total transaction of $271,140.00. Following the completion of the transaction, the insider owned 142,745 shares in the company, valued at approximately $8,564,700. This represents a 3.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Regina E. Groves sold 5,313 shares of the firm’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $54.22, for a total transaction of $288,070.86. Following the transaction, the director directly owned 34,546 shares of the company’s stock, valued at $1,873,084.12. The trade was a 13.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 74,868 shares of company stock worth $3,317,897. Insiders own 4.00% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. BlackRock Inc. bought a new position in AtriCure during the second quarter valued at approximately $125,198,000. Wellington Management Group LLP increased its stake in AtriCure by 3.3% in the 2nd quarter. Wellington Management Group LLP now owns 3,495,603 shares of the medical device company’s stock worth $97,807,000 after acquiring an additional 113,048 shares during the last quarter. GW&K Investment Management LLC raised its holdings in shares of AtriCure by 10.6% during the 4th quarter. GW&K Investment Management LLC now owns 952,089 shares of the medical device company’s stock worth $37,665,000 after acquiring an additional 91,054 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of AtriCure by 8.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 997,759 shares of the medical device company’s stock valued at $28,466,000 after acquiring an additional 75,862 shares during the last quarter. Finally, Bank of America Corp DE bought a new position in shares of AtriCure during the 2nd quarter valued at approximately $24,465,000. Hedge funds and other institutional investors own 99.11% of the company’s stock.

About AtriCure

AtriCure, Inc is a medical device company focused on developing and commercializing technologies for the treatment of atrial fibrillation (AF) and related cardiac conditions. Its products are used primarily in cardiac surgery and electrophysiology procedures to create surgical lesions that interrupt abnormal electrical signals in the heart.

The company’s portfolio includes the AtriCure Isolator Synergy ablation system, cryoablation products sold under the cryoICE brand, and the AtriClip system for the exclusion of the left atrial appendage, a potential source of blood clots in patients with AF.